Defective innate immunity in inflammatory bowel disease: A Crohn's disease exclusivity?

Current Opinion in Gastroenterology

Volumn 27, Issue 4, 2011, Pages 328-334

  Marks, Daniel J B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

autophagy; Crohn's disease; immunodeficiency; neutrophil; ulcerative colitis

Indexed keywords

ANTIINFECTIVE AGENT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; DEFENSIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ATYPICAL MYCOBACTERIOSIS; AUTOPHAGY; BACTERIAL CLEARANCE; CELL STRUCTURE; CONGENITAL DISORDER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE MODEL; DISEASE PREDISPOSITION; ENTERITIS; EPITHELIUM CELL; ESCHERICHIA COLI; GENETIC ASSOCIATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; LYMPHOCYTE; MACROPHAGE FUNCTION; META ANALYSIS (TOPIC); MUCOSA CELL; MYCOBACTERIUM PARATUBERCULOSIS; NEUTROPHIL; NONHUMAN; OBSERVATIONAL METHOD; PATHOGENESIS; PERMEABILITY BARRIER; PHENOTYPE; PROTEIN POLYMORPHISM; REVIEW;

CROHN DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTESTINAL MUCOSA;

EID: 79958774972     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283463b45     Document Type: Review

References (55)

1. Sewell GW, Marks DJ, Segal AW. The immunopathogenesis of Crohn's disease: a three-stage model. Curr Opin Immunol 2009; 21:506-513.
2. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006; 367:668-678. (Pubitemid 43289157)
3. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009; 206:1883-1897. This report demonstrates impaired bacterial clearance in vivo in Crohn's patients and localizes the defect in macrophage cytokine secretion to premature trafficking of proteins to the lysosomal compartment.
4. Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009; 206:1839-1843.
5. Shen L, Su L, Turner JR. Mechanisms and functional implications of intestinal barrier defects. Dig Dis 2009; 27:443-449.
6. Jager S, Stange EF, Wehkamp J. Antimicrobial peptides in gastrointestinal inflammation. Int J Inflamm 2010; 2010:910283.
7. Rumessen JJ, Vanderwinden JM, Horn T. Crohn's disease of the colon: ultrastructural changes in submuscular interstitial cells of Cajal. Cell Tissue Res 2011; 343:421-428.
8. Kiba T. Relationships between the autonomic nervous system, humoral factors and immune functions in the intestine. Digestion 2006; 74:215-227. (Pubitemid 46622793)
9. Yamamoto-Furusho JK, Barnich N, Hisamatsu T, et al. MDP-NOD2 stimulation induces HNP-1 secretion, which contributes to NOD2 antibacterial function. Inflamm Bowel Dis 2010; 16:736-742.
10. Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol 2010; 184:6688-6694.
11. Kosovac K, Brenmoehl J, Holler E, et al. Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflamm Bowel Dis 2010; 16:1311-1321.
12. Gutierrez A, Holler E, Zapater P, et al. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. Inflamm Bowel Dis 2010. [Epub ahead of print]
13. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132:2313-2319. (Pubitemid 46890859)
14. Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010; 50:473-480. A meta-analysis of 16 trials suggesting the benefit of antimycobacterial chemotherapy in Crohn's disease.
15. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med 2009; 361:2609-2618.
16. Berrington WR, Macdonald M, Khadge S, et al. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J Infect Dis 2010; 201:1422-1435.
17. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and antitumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15:1556-1561. Postmarketing surveillance data showing that antitumour necrosis factor therapy increases the risk of nontuberculous mycobacterial infection, particularly Mycobacterium avium species.
18. Desai AA, Marks DJ. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease. Expert Rev Clin Immunol 2010; 6:695-699.
19. Lalande JD, Behr MA. Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation. Expert Rev Clin Immunol 2010; 6:633-641. A review article that synthesizes the data on mycobacteria in Crohn's disease, and discusses how these might relate to impaired innate immunity.
20. Lapaquette P, Darfeuille-Michaud A. Abnormalities in the handling of intracellular bacteria in Crohn's disease. J Clin Gastroenterol 2010; 44 (Suppl 1):S26-S29.
21. Sepehri S, Khafipour E, Bernstein CN, et al. Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis 2010. [Epub ahead of print]
22. Nash JH, Villegas A, Kropinski AM, et al. Genome sequence of adherent-invasive Escherichia coli and comparative genomic analysis with other E. coli pathotypes. BMC Genomics 2010; 11:667. One of two studies publishing the genome sequence of adherent-invasive E. coli, an organism that evades innate immune defences and may be of pathogenic relevance in Crohn's disease.
23. Miquel S, Peyretaillade E, Claret L, et al. Complete genome sequence of Crohn's disease associated adherent-invasive E. coli strain LF82. PLoS One 2010; 5. The second study reporting the genome sequence of adherent-invasive E. coli.
24. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603. (Pubitemid 32531408)
25. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606. (Pubitemid 32531409)
26. Magalhaes JG, Sorbara MT, Girardin SE, Philpott DJ. What is new with Nods? Curr Opin Immunol 2011; 23:29-34.
27. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955-962.
28. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11:55-62. A study revealing a direct interaction between the proteins encoded by the two principal susceptibility genes for Crohn's disease and demonstrating that the polymorphisms result in loss-of-function culminating in impaired bacterial killing.
29. Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 2010; 139:1630-1641.
30. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16:90-97. A study demonstrating that the Crohn's disease-associated mutations in CARD15 and ATG16L1 impair bacterial processing and antigen presentation.
31. Sabbah A, Chang TH, Harnack R, et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009; 10:1073-1080. A study that identifies an extended spectrum of innate immune activity of Nod2 to include responsiveness to viral infection.
32. ShawMH, Reimer T, Sanchez-Valdepenas C, et al. T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat Immunol 2009; 10:1267-1274.
33. Clarke TB, Davis KM, Lysenko ES, et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010; 16:228-231.
34. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009; 41:71-76.
35. Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2010. [Epub ahead of print]
36. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42:1118-1125. The most recent update of genome-wide association studies in Crohn's disease. The 39 novel susceptibility loci identified elevate the total number to 71.
37. Maher B. Personal genomes: the case of the missing heritability. Nature 2008; 456:18-21.
38. Marks DJ, Miyagi K, Rahman FZ, et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 2009; 104:117-124. A case series demonstrating that Crohn's-like inflammatory bowel disease arises in approximately 50% of patients with chronic granulomatous disease.
39. Rahman FZ, Marks DJ, Hayee BH, et al. Phagocyte dysfunction and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1443-1452.
40. Diez R, Garcia MJ, Vivas S, et al. Gastrointestinal manifestations in patients with primary immunodeficiencies causing antibody deficiency. Gastroenterol Hepatol 2010; 33:347-351.
41. Marks DJ, Seymour CR, Sewell GW, et al. Inflammatory bowel diseases in patients with adaptive and complement immunodeficiency disorders. Inflamm Bowel Dis 2010; 16:1984-1992.
42. Freudenberg F, Wintergerst U, Roesen-Wolff A, et al. Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease. J Allergy Clin Immunol 2010; 125:943-946.
43. Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factoralpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 51:1429-1434.
44. Hayee B, Rahman FZ, Tempero J, et al. The neutrophil respiratory burst and bacterial digestion in Crohn's disease. Dig Dis Sci 2010. [Epub ahead of print]
45. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005; 352:2193-2201. (Pubitemid 40727086)
46. Kelsen JR, Rosh J, Heyman M, et al. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis 2010; 16:1203-1208.
47. Panes J, Ordas I, Ricart E. Stem cell treatment for Crohn's disease. Expert Rev Clin Immunol 2010; 6:597-605.
48. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005; 128:552-563. (Pubitemid 40585356)
49. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59:1662-1669.
50. Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis 2010; 16:507-511.
51. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-977.
52. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29:19-20. (Pubitemid 32801800)
53. Marks DJ, Rahman FZ, Novelli M, et al. An exuberant inflammatory response to E. coli: implications for the pathogenesis of ulcerative colitis and pyoderma gangrenosum. Gut 2006; 55:1662-1663. (Pubitemid 44629220)
54. Rahman FZ, Smith AM, Hayee B, et al. Delayed resolution of acute inflammation in ulcerative colitis is associated with elevated cytokine release downstream of TLR4. PLoS One 2010; 5:e9891. A study examining the innate immune response in ulcerative colitis provides no evidence of immunodeficiency but reveals that inflammation resolution is defective.
55. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40:713-715. (Pubitemid 351748866)